Bolt Biotherapeutics, Inc. (BOLT) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$6.53

From 52W high−8.67%

Volume1985.00

Market cap$15.26M

P/E (TTM)—

P/S (TTM)3.2x

Div yield—

Key dataNov 4, 2026

Open

$6.53

From 52W high

−8.67%

Volume

1985.00

Market cap

$15.26M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.7x

P/E (TTM)

—

RSI (14)

68.4

MomentumView details →

1D Return

−1.45%

YTD Return

+14.29%

SummaryUpdated Jun 1, 2026

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) is a clinical-stage biotechnology company founded in 2015 and headquartered in Redwood City, California. The company went public in February 2021 and focuses on developing innovative immuno-oncology therapies designed to harness the body's immune system to eliminate cancer cells. Originally incorporated as Bolt Therapeutics, Inc., the company changed its name to Bolt Biotherapeutics in July 2015 to better reflect its focus on biological therapeutics. The company has undergone significant strategic restructuring in recent years, including substantial workforce reductions and pipeline prioritization to extend its operational runway.

Ask drillr about Bolt Biotherapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.7x

EV/Sales

4.1x

P/S (TTM)

3.2x

P/B (TTM)

1.2x

ProfitabilityView details →

Gross Margin

95.68%

Net Margin

−611.47%

EBITDA Margin

−591.91%

ROE (TTM)

−227.37%

ROA (TTM)

−71.23%

Asset Turnover

0.11x

GrowthView details →

Revenue YoY

+12.79%

EPS YoY

—

FCF YoY

+38.64%

Revenue CAGR 3Y

+10.33%

EPS CAGR 3Y

—

EBITDA YoY

+44.77%

MomentumView details →

1D Return

−1.45%

YTD Return

+14.29%

1Y Return

+24.05%

RSI (14)

68.4

vs 50D SMA

+47.50%

vs 200D SMA

+38.82%

Capital & dividendView details →

Debt/Equity

1.71x

Current Ratio

2.61x

Quick Ratio

2.61x

Div Yield

—

Div Rate

—

Div Growth 1Y

−15.62%

EarningsView details →

EPS (Actual)

−$4.57

EPS Surprise

−34.81%

Beats (12Q)

7/12

Next Q EPS Est

−$3.85

Avg Surprise (4Q)

−5.57%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

4.70M

Net Income (TTM)

−28.74M

Op. CF (TTM)

−31.45M

Next earningsNov 11, 2026 →

Latest newsMore news →

Bolt Biotherapeutics appointed Sheila Gujrathi as a Class II director and Chief Strategy Officer, effective October 23, 2026.12d ago

Bolt Biotherapeutics amended its lease with HCP LS Redwood City LLC, accelerating the lease expiration to December 31, 2027, or earlier upon a Corporate Transaction, and providing for a $4.5 million termination payment upon such a transaction.29d ago

Similar companies

Hoth Therapeutics, Inc.HOTH Citius Pharmaceuticals, Inc.CTXR Jasper Therapeutics, Inc.JSPR Dyadic International, Inc.DYAI Tevogen Bio Holdings Inc.TVGNW Pluri Inc.PLUR Find similar companies →

Latest newsMore news →

Bolt Biotherapeutics appointed Sheila Gujrathi as a Class II director and Chief Strategy Officer, effective October 23, 2026.12d ago Bolt Biotherapeutics amended its lease with HCP LS Redwood City LLC, accelerating the lease expiration to December 31, 2027, or earlier upon a Corporate Transaction, and providing for a $4.5 million termination payment upon such a transaction.29d ago